SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Emotional wellness Matters: My Fight with Tension - 2Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- 3An Extended period of Voyaging Carefully: the World with Reason
- 4New heart disease calculator predicts 30-year risk for young adults
- 5Foot fossil discovery could reshape human evolutionary history
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- The Ascent of the Kona SUV: How Hyundai's Reduced Hybrid Is Vanquishing the Streets
- WHO suspends medical evacuations from Gaza following death of contractor in 'security incident'
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- Improving as a Cook: Culinary Experiences in the Kitchen
- Collection of 7,000-year-old ostrich eggs discovered under sand dunes in southern Israel
